p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2

Molecular Cancer Research

Volumn 3, Issue 11, 2005, Pages 627-634

  Aliouat Denis, Cécile Marie ^a   Dendouga, Najoua ^a   Van Den Wyngaert, Ilse ^a   Goehlmann, Hinrich ^a   Steller, Ulf ^a   Van De Weyer, Inez ^a   Van Slycken, Nele ^a   Andries, Luc ^b   Kass, Stefan ^a   Luyten, Walter ^a   Janicot, Michel ^a   Vialard, Jorge E ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b HistoGeneX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOGENESIS; CELL AGING; CELL CYCLE; CELL IMMORTALIZATION; CONTROLLED STUDY; DNA CONTENT; DNA DAMAGE; FLUORESCENCE MICROSCOPY; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CARCINOMA; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE;

APOPTOSIS; BREAST NEOPLASMS; CELL AGING; CELL DIVISION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATINOCYTES; LUNG NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RETROVIRIDAE; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 28844462784     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0121     Document Type: Article

References (40)

1. Ahn J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair 2004;3: 1039-47.
2. Bartek J, Falck J, Lukas J. CHK2 kinase - a busy messenger. Nat Rev Mol Cell Biol 2001;2:877-86.
3. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-8.
4. Gire V, Roux P, Wynford-Thomas D, Brondello J-M, Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J 2004;3:2554-63.
5. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004;23:2919-33.
6. Roninson IB. Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities in stromal fibroblasts. Cancer Lett 2002;179:1-14.
7. Kahlem P, Dorken B, Schmitt CA. Cellular senescence in cancer treatment, friend or foe? J Clin Invest 2004;113:169-74.
8. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003;63: 2705-15.
9. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68.
10. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-9.
11. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432: 316-23.
12. Fei P, El Deiry WS. P53 and radiation responses. Oncogene 2003;22:5774-83.
13. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22: 9030-40.
14. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 2000;60:5934-6.
15. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998;282:1893-7.
16. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000;14:289-300.
17. Lukas C, Bartkova J, Latella L, et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res 2001;61:4990-3.
18. Tominaga K, Morisaki H, Kaneko Y, et al. Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53. J Biol Chem 1999;274:31463-7.
19. Schwarz JK, Lovly CM, Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol Cancer Res 2003;1:598-609.
20. Xu X, Tsvetkov LM, Stern DF. Chk2 activation and phosphorylation- dependent oligomerization. Mol Cell Biol 2002;22:4419-32.
21. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
22. Meek DW. The p53 response to DNA damage. DNA Repair 2004;3:1049-56.
23. Damia G, Sanchez Y, Erba E, Broggini M. DNA damage induces p53-dependent down-regulation of hCHK1. J Biol Chem 2001;276:10641-5.
24. Gottifredi V, Kami-Schmidt O, Shieh SS, Prives C. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol Cell Biol 2001;21:1066-76.
25. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-57.
26. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-22.
27. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002;303:124-31.
28. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 1995;92:5545-9.
29. Hedenfalk IA, Baldetorp B, Borg A, Oredsson SM. Activated cell cycle checkpoints in epirubicin-treated breast cancer cells studied by BrdUrd-flow cytometry. Cytometry 1997;29:321-7.
30. Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000;287:1824-7.
31. Gartel AL, Tyner AL. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999;246:280-9.
32. Chen CR, Wang W, Rogoff HA, Li X, Mang W, Li CJ. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res 2005;65:6017-21.
33. Schmitt CA. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer 2003;3:286-95.
34. INK4a contributes to the outcome of cancer therapy. Cell 2002;109: 335-46.
35. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62: 1876-83.
36. Lorens JB, Bennett MK, Pearsall DM, et al. Retroviral delivery of peptide modulators of cellular functions. Mol Ther 2000;1:438-47.
37. Swift SE, Lorens JB, Achacoso P, Nolan GP. Current protocols in immunology. In: Coligan RCJE, Kruisbeek A, Margulies DH, Shevach EM, Strober W, editors. Vol. 10.17C. New York: Wiley; 1999. p. 1-17.
38. Vindelov LL. Flow cytometric DNA analysis. Eur J Respir Dis 1985;66:313-4.
39. De Schepper S, Bruwiere H, Verhulst T, et al. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J Pharmacol Exp Ther 2003;304:881-8.
40. Kockx MM, Muhring J, Knaapen MW, De Meyer GR. RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. Am J Pathol 1998;152:885-8.